FDA Fast-Tracks Psilocybin and Methylone for Mental Health Following Trump Directive

WASHINGTON — The U.S. Food and Drug Administration (FDA) took a significant step toward the potential approval of psychedelic-based medicines on Friday, issuing national priority vouchers to three companies studying psilocybin and methylone. The move is designed to fast-track the review process for treatments targeting treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder (PTSD).

‎

The regulatory shift follows a landmark executive order signed last Saturday by President Donald Trump, which directed FDA Commissioner Dr. Marty Makary to prioritize psychedelic drugs that have been granted "breakthrough therapy" status. The order also includes a $50 million investment to help state governments study how these therapies can address the nation’s escalating mental health crisis, with a particular focus on the needs of military veterans.

‎

Health and Human Services Secretary Robert F. Kennedy Jr. highlighted the administration's commitment to "confront our nation’s mental health crisis head-on." The new priority vouchers could significantly shorten the FDA's review timeline, potentially cutting a process that usually takes several months down to just a few weeks. Commissioner Makary noted that while these medications show great promise for conditions like treatment-resistant depression and substance abuse, they must be evaluated with "urgency" and grounded in rigorous clinical evidence.

‎

In an unprecedented move, the FDA also authorized the first-ever clinical study in the United States for ibogaine, a psychedelic derived from an African plant, as a potential treatment for alcohol use disorder. Although the agency cautioned that this authorization does not constitute an approval of the drug's safety or efficacy, it allows researchers to begin formal evaluation in a controlled clinical setting. Makary clarified that if these drugs are eventually approved, they will be administered under strict supervision in hospitals rather than through traditional pharmacies.

‎

Advocacy groups, such as the Psychedelic Medicine Coalition, praised the decision, noting that it "greases the wheels" for psychedelic medicines to enter mainstream healthcare. However, the American Psychiatric Association (APA) urged caution, welcoming the federal investment in research but stressing that current scientific evidence is not yet sufficient to support the use of these therapies outside of approved research settings. The APA is calling for physician-led oversight and strong patient protections to ensure that any new treatments are both safe and effective.

‎

As the FDA prepares to release final guidance for sponsors developing these products, the move marks a dramatic shift in federal drug policy. The emerging field of psychedelic medicine is increasingly being viewed not as a fringe concept, but as a critical component of the U.S. mission to lead the world in advanced, outcomes-driven mental health care.

‎

Explore: NBCPalmSprings.com, where we are connecting the Valley.